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Background
Progressive multifocal leukoencephalopathy (PML) is
caused by reactivation of JC virus (JCV) infection. To
determine whether the bone marrow (BM) is a site of viral
reactivation, we compared the prevalence of JCV infection
in archival BM biopsy samples and fresh BM aspirates of
HIV+ and HIV- patients without PML, and characterized
the phenotype of JCV-infected cells.
Results
Of 41 HIV+ patients, 38 were male (93%) and indications
for BM biopsies were lymphoma (20), pancytopenia (8),
anemia (6), MGUS (2), polycythemia (2), leucopenia (1),
splenomegaly (1), and thrombocytopenia (1). Mean age
was 47 (range 32–71), mean CD4 count 211 (2–928),
27% had undetectable plasma HIV RNA, and 75% were
on HAART. The 47 HIV- controls, matched for indications
for BM biopsy, included 32 males (65%), and mean age
was 56 (range 27–93). Quantitative PCR detected JCV
DNA in BM samples of 19/41 (46%) HIV+ vs 3/47 (6%) of
HIV- (p < 0.001). Preliminary immunohistochemistry
(IHC) experiments suggest that JCV T antigen is detectable
in a fraction of JCV DNA positive bone marrows samples,
while JCV VP1 protein was not. Furthermore, JCV was
detected by double IHC in some of the plasma cells, mye-
loid, and lymphoid cells. We then tested fresh BM aspi-
rates, blood and urine samples from 30 HIV- and 6 HIV+
patients. JCV DNA was detectable in 10/36 (28%) fresh
BM aspirates, 7/26 (27%) peripheral blood samples, and
9/20 (45%) urine samples. In HIV+patients, 3/6 (50%)
had detectable JCV DNA in BM aspirates vs 7/30(23%) of
HIV- patients. The JCV+-cell subpopulations in HIV+
patients included B, T, NK and NKT cells, with a JC viral
load ranging from 2–1080 copies/ug DNA, while HIV-
patients had JCV in the same subpopulations, as well as
PMN and monocytes, with a viral load ranging from 2–
250 copies/ug DNA. Six of the HIV+ and one HIV- bone
marrow samples underwent RR amplification by PCR.
Analysis of JCV regulatory sequence is in progress and will
be presented.
Conclusion
JCV is not present in BM of most HIV- individuals who
required bone marrow biopsy, which suggests that BM is
not a common reservoir for JCV in HIV- individuals. How-
ever, half of HIV+ patients harbored JCV in their BM. JCV
reactivation in BM may require profound immunosup-
pression as seen in HIV infection, and potentially specific
depletion of CD4+ and CD8+ T cells.
from Infectious diseases of the nervous system: pathogenesis and worldwide impact
Paris, France. 10–13 September 2008
Published: 23 September 2008
BMC Proceedings 2008, 2(Suppl 1):P66
<supplement> <title> <p>Infectious diseases of the nervous system: pathogenesis and worldwide impact</p> </title> <editor>Roberto Bruzzone, Monique Dubois-Dalcq, Georges E Grau, Diane E Griffin and Krister Kristensson</editor> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1753-6561-2-S1-full.pdf">here</a>.</note> </supplement>
This abstract is available from: http://www.biomedcentral.com/1753-6561/2/S1/P66
© 2008 Tan et al; licensee BioMed Central Ltd. 
